Judge Finds Watson Infringed Elan's Naprelan Patent

Law360, New York (August 14, 2008, 12:00 AM EDT) -- In the second round of a decade-old patent battle, a federal judge has found that Watson Pharmaceuticals Inc. willfully infringed the patent for Elan Corp.'s anti-inflammatory drug Naprelan, a patent once ruled invalid but revived on appeal.

U.S. District Judge Adalberto Jordan of the Southern District of Florida ruled Tuesday that Watson's naproxen sodium ER tablets infringe Claim 1 of the patent-in-suit and 11 dependent claims, both literally and under the doctrine of equivalents.

In a 206-page opinion, Judge Jordan concluded that Andrx Pharmaceuticals Inc., now...
To view the full article, register now.